Michael K. Schultz, PhD
BA, Russian Language, University of South Florida, 1990
MS, Marine Chemistry, Florida State University, 1996
PhD, Chemical Oceanography (Actinide Biogeochemistry), Florida State University, 2002
PRECLINICAL CANCER RESEARCH - IMAGE-GUIDED THERAPY FOR METASTATIC MELANOMA
Dr Schultz's research involves developing a detailed understanding of differences in cancer cell metabolism and cell surface antigen expression - and exploiting these differences to develop novel image-guided therapies for cancer - with a focus on metastatic melanoma. This research focuses on differences in mitochondrial oxidative metabolism of metastatic melanoma cells relative to normal cells, which leads to identifiable metastatic-melanoma cell characteristics and antigen expression, which can be targeted for image-guided therapies using peptides and small molecules. The Schultz lab specializes in identifying these unique cancer-cell specific characteristics and synthesizing small molecules and peptides that target them for image-guided therapy for cancer. Within this context, the Schultz lab has identified and submitted provisional patents for a new class of cancer therapy drugs that target specific mitochondrial targets for therapy of metastatic melanoma. The Schultz lab has further identified two cell surface targets and accompanying peptide and small molecule targeting ligands that can be used for imaged-guided targeted radionuclide therapy for metastatic melanoma and is advancing these compounds toward clinical trials.
ENTREPRENEURSHIP AND TECHNOLOGY TRANSFER
Dr Schultz is actively involved in entrepreneurial activities to move discoveries toward technology transfer and commercialization. His company, Viewpoint Molecular Targeting, LLC (www.viewpointmt.com) develops innovative image-guided therapies for cancer, with a focus on metastatic melanoma. The company recently secured resources through an agreement with strategic partner Radiomedix, Inc. (www.radiomedix.com), to begin preclinical imaging and biodistribution studies of newly discovered and co-developed agents in licensed facilities in Houston, TX. Company development activities and highlights include:
- 2010 University of Iowa Fastrack Entrepreneurial Workshop (10 weeks)
- 2011 $25,000 Grand Prize UI Business Plan/Elevator Pitch Competition
- 2012 Keynote Address at the UI Entrepreneurial Bootcamp (CSO Michael K Schultz PhD)
- 2013 $5,000 UI Innovation Summit Business Model Competition Award for Biotech Business Model Innovation
- 2013 Distinguished Inventor Award, UI Innovation Summit (CSO Michael K Schultz PhD)
RADIOCHEMISTRY AND NUCLEAR FORENSICS RESEARCH
Dr Schultz leads the effort in the Department of Radiology to develop a broad curriculum and research agenda in radiochemistry. These efforts span a spectrum of applications involving the radiochemistry of the elements for nuclear forensics, environmental science (geochronology), geochemistry and marine radiochemistry, as well as radiopharmaceutical research, nuclear medicine and cancer research. These efforts have lead to relevant findings concerning the geochemical fractionation of actinides in soils, sediments, and natural waters in field studies conducted in collaboration with the Savannah River and Oak Ridge National Laboratories, as well as the Ionizing Radiation Division at the National Institute of Standards and Technology.
DOE National Analytical Management Program
NAMP Radiochemistry Training Program
DOE NAMP Homepage
Schultz Lab Contributes to National Radiochemistry Webinar Series
Publications in Radiochemistry (Environmental and Nuclear Forensics)
RADIOCHEMISTRY COMMUNITY SERVICE
1st World Congress on Ga-68
(Generators and Novel Radiopharmaceuticals), Molecular Imaging (PET/CT),
Targeted Radionuclide Therapy & Dosimetry (FWC-2011)
Dates: June 23-26, 2011
Bad Berka, Germany
Serving as: Scientific Advisory Committee
2nd World Congress on Ga-68
Complete Compilation of 2nd World Congress of Videotaped Oral Presentations
(Generators and Novel Radiopharmaceuticals), Molecular Imaging (PET/CT),
Targeted Radionuclide Therapy & Dosimetry (SWC-2013)
Dates: 28th February-2nd March, 2013
Serving as: Conference Vice President
Conference Home Page
TEACHING IN RADIOCHEMISTRY
Dr Schultz is working with Assistant Professor Tori Forbes PhD in the Department of Chemistry to advance new curriculum in radiochemistry at the University of Iowa. These efforts have led to a new BA in Chemistry with a Radiochemistry Focus, as well as formalized coursework in radiochemistry that begins in the Fall Semester, 2013. For more information on the radiochemistry program at the University of Iowa, please contact Dr Schultz (email@example.com) or Course Director Dr Tori Forbes PhD (firstname.lastname@example.org) in the Department of Chemistry. Also see:
Degrees in Chemistry (including the BA Chemistry (Radiochemistry Focus)
Curriculum in Radiochemistry
HONORS, AWARDS, GUEST RESEARCHER AFFILIATIONS AND ORGANIZATIONS
Fulbright Specialist Roster appointment for Radiochemistry (Awarded 07-05-2013). Dr Schultz has been appointed to the Fulbright Specialist Roster by the J William Fulbright Foreign Scholarship Board, the US Department of State's Bureau of Education and Cultural Affairs, and the Council for International Exchange of Scholars under the Fulbright Specialist Program (http://fulbright.ru). Dr Schultz will be working with Professor Lydia Bondareva (http://icmim.sfu-kras.ru/bondareva) and colleagues at Siberian Federal University (http://www.sfu-kras.ru) on curriculum development for environmental radiochemistry, nuclear forensics, and radiopharmaceutical science.
Recent Invited Presentations (National and International)
- Schultz MK. (2012). Gordon Research Conference – Metals in Medicine. Radiochemistry and PET Imaging Applications of Generator Based Gallium-68. Invited Presenter. Andover, NH. June.
- Schultz MK. (2012). Chelator additions to peptides for molecular imaging by ring strain promoted copper free click chemistry. Invited Faculty Continuing Education Seminar. Society of Nuclear Medicine Annual Meeting, Miami, FL. June 9.
- Schultz MK. (2012). Molecular Imaging Advances for Pediatrics – [68Ga]DOTATOC and the horizon for PET imaging of pediatric cancers. Invited Faculty Presentation. Pediatric Council Meeting. Society of Nuclear Medicine Annual Meeting. Miami, FL. June 11.
- Schultz MK. (2012). Radionuclides for Molecular Imaging and Therapy of Cancer. Invited Faculty Lecture, Oregon State University, Host Alena Paulenova, Professor of Radiochemistry. April, 2012.
Member, American Chemical Society
Guest Researcher, Oak Ridge National Laboratory
Member, American Association for the Advancement of Science
Member, Society of Nuclear Medicine (Pediatric Council 2007)
Member, International Society of Radiopharmaceutical Sciences
Fraternal Order of the Eagles (Iowa Aerie) Research Award - 2007
Fraternal Order of the Eagles (Iowa Aerie) Research Award — Childhood Cancer - 2009
- Schultz MK, Mueller D, Watkins GL, Breeman WAP. (2012). A new automated NcCl based robust method for routine production of gallium-68 labeled peptides. Appl. Rad. Isot., In Press.
- Mueller D, Klette I, Baum RP, Schultz MK, Breeman WAP. (2012). Simplified NaCl Based 68Ga Concentration and Labeling Procedure for Rapid Synthesis of 68Ga Radiopharmaceuticals in High Radiochemical Purity. Bioconjug. Chem. Aug 15;23(8) 1712-1717. PMID: 22755505
- Martin ME, O'Dorisio MS, Leverich WM, Kloepping KC, Walsh SA, Schultz MK. (2012). "Click"-cyclized (68)ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system. Recent Results Cancer Res. 194:149-75. PMID: 22918759
- Baumhover NJ, Martin ME, Parameswarappa SG, Kloepping KC, O'Dorisio MS, Pigge FC, Schultz MK. Improved synthesis and biological evaluation of chelator-modified α-MSH analogs prepared by copper-free click chemistry. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5757-61. PMID: 21873053
- Rockey WM, Huang L, Kloepping KC, Baumhover NJ, Giangrande PH, Schultz MK. Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. (2011) Bioorg. Med. Chem. 2011 Jul 1;19(13):4080-90. PMID: 21658962
- Ndiege N, Renugan R, Schultz MK, and Larsen SC. Preparation of a Versatile Bifunctional Zeolite Nanoparticles for Targeted Imaging Applications. (2011). Langmuir, In Press, January.
- Martin ME, Paramaswarappa SG, O'Dorisio MS, Pigge FC, and Schultz MK. A DOTA-peptide conjugate by copper-free click chemistry. (2010). Bioorg. & Med. Chem. Lett., Aug 15;20(16):4805-7. PMID 20630750.
- Schultz MK, Paramaswarrappa SG, and Pigge FC. Synthesis of a DOTA-Biotin Conjugate for Radionuclide Chelation via Copper-Free Click Chemistry. (2010). Org. Let., 12(10):2398-401
- Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Gupta AK, McGuire S, Anderson C, Schultz MK, Sunderland JJ, Graham MM, and Buatti JM. Investigation of Pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine (FLT) Uptake in the Bone Marrow Prior to and Early After Initiation of Chemoradiation Therapy in Head and Neck Cancer. (2010). Nucl. Med. Biol. May;37(4):433-8. PMID: 204475543.
- Menda Y, Boles-Ponto LL, Dornfield K, Tewson TJ, Clark J, Richmond J, Watkins GL, Schultz MK, Sunderland J, Graham M, and Buatti JM. Kinetic analysis of 3'-deoxy-3'-[18F]fluorothymidine (FLT) in head and neck cancer patients prior to and early after initiation of chemoradiation therapy. (2009). J. Nucl. Med. 50;1028-1035. PMID: 19525472
- Cessna JT, Schultz MK, Leslie T, and Bores N. Radionuclide calibrator measurements of 18F in a 3 ml plastic syringe. (2008). App. Rad. Isot. 66(6-7):988-993. PMID:18375134
- Fitzgerald R, and Schultz MK. Liquid scintillation-based anticoincidence counting of 60Co and 210Pb. (2008). App. Rad. Isot. 66(6-7):937-940. PMID:18342524.
- Schultz MK, Cessna JT, Ponto JA, Kowalsky RJ, Palmer MR, Beinlich UF, Divgi C, and Norenberg JP. A performance evaluation of 90Y dose calibrator measurements in nuclear pharmacies and clinics in the United States. (2008). Appl. Rad. Isot. 66:252-260. PMID:17933545
- Schultz MK, Borgman MP, Coleman T, Bakhlanov S, Marchenkov N, and Line BR. An assessment of radionuclidic impurities of 210Po produced via neutron irradiation of 209Bi for use in targeted alpha-particle radiotherapy. (2007). Appl. Rad. Isot. 65:784-792. PMID:17466524.
- Schultz MK, Hammond MH, Cessna JT, Plascjak P, Norman B, Szajak L, Garmestani K, Zimmerman BE, and Unterweger M. Assessing the 210At impurity in the production of 211At for radiotherapy by 210Po analysis via isotope dilution alpha spectrometry. (2006). Appl. Rad. Isot., 64:1365-1369. PMID:16563782.
RECENT INVITED PRESENTATIONS AND RELEVANT ABSTRACTS:
- Martin ME, Schafer B, Shutt DC, Kloepping KC, Walsh S, Boles-Ponto LL, Weiland NA, O’Dorisio TO, O’Dorisio MS, Schultz MK. Development of gallium-68 labeled neuropeptide Y analogs for imaging neuroblastoma. (2010). 42nd Annual Society of Nuclear Medicine India Meeting, Invited Visiting Faculty Presentation, November 10-15, 2010; Chandigarh, India.
- Schultz MK and Baum, RP. 68Ga-Labeled Neuropeptides for Imaging and Therapy of Neuroendocrine Tumors: Radiochemistry of 68Ga for Radiopharmaceutical Preparations and Clinical Applications; Invited Continuing Medical Education (CME) Seminar; Society of Nuclear Medicine Annual Meeting, June, (2010). Salt Lake City, UT.
- Mueller D, Gottschaldt M, Klette I, Schultz MK, Baum RP. Ga-68 Labeled Sugar Substituted Tripodal Trisalicylidene Imines. Society of Nuclear Medicine Annual Meeting, June, (2010). Salt Lake City, UT. J Nucl. Med. 51 (Supplement 2):1546.
- Martin ME, Calva-Cerqueira D, Schafer BS, Leverich W, Schultz MK, Shutt DC, O'Dorisio TM, O'Dorisio MS, Howe J (2010). Tomography Imaging Targets in Ileal and Pancreatic NET. Pancreas. 39(2):275. doi: 10.1097/01.mpa.0000363924.01220.ce.
- Schultz MK, Shutt DC, Weiland NA, White N, Schafer BS, Martin ME, Boles-Ponto LL, Walsh SA, O'Dorisio TM, O'Dorisio MS (2010). 68Ga labeled NPY analogs for imaging NET by PET. Pancreas. 39(2):280. doi:10.1097/01.mpa.0000363944.74777.2f.
Radiochemistry and Cancer Research Lab (RCRL):